Actively Recruiting
Randomized Phase 2 Trial Comparing Fruquintinib with and without TAS-102 in Adults with Refractory Advanced or Metastatic Colorectal Cancer
Led by Criterium, Inc. · Updated on 2026-10-15
120
Participants Needed
13
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial investigates treatment options for adults with refractory advanced or metastatic microsatellite stable colorectal cancer. It aims to compare the effects of combining two drugs, Fruquintinib and TAS-102, versus Fruquintinib alone in patients whose cancer has not responded to standard therapies. The study is a randomized phase 2 trial sponsored by Criterium, Inc., focusing on evaluating treatment benefits in this patient group. Participants are randomly assigned to one of two groups one group receives Fruquintinib combined with TAS-102, while the other receives Fruquintinib alone. Both treatments are oral medications given according to the study protocol. The study uses a parallel design without masking, meaning both participants and researchers know which treatment is given. The trial plans to observe effects over 24 months, focusing on progression-free survival and other clinical outcomes. Throughout the study, participants undergo regular assessments including tumor measurements using RECIST criteria, laboratory tests, and evaluations of side effects. Researchers monitor disease control, response rates, clinical benefits, survival, and treatment toxicity. Participants will be followed for up to two years to collect comprehensive safety and effectiveness data, with careful monitoring by the study team during this period.
CONDITIONS
Brief Title
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Research Team
S
Soumaya Chappidi
J
Julee Hartwell
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here